

Department of Consultation-Liaison Psychiatry

Contact: Conjoint Associate Professor Gregory Carter

P: +61 (0) 249211283

F: +61 (0) 249211870

E: Gregory.Carter@newcastle.edu.au

Research Staff:

Conjoint Assoc. Professor Gregory Carter MB.BS. FRANZCP Cert Child Psych. PhD.

Jennifer Bryant - Conjoint Lecturer R.N., B. Nurs. M. Nurs., MCN, MACMHN

Catherine Adams - CINSW Clinical Fellow (Research)

Dr Kerrie Clover – Research Manager

Mr Benjamin Britton – Professional Doctorate student, Health Psychology

Ms Louisa Gianacas – Professional Doctorate student, Clinical Psychology

Research Interests

- Suicide prevention and Suicide Epidemiology
- Psycho-oncology
- Delirium and Toxicology of psycho-active medications
- Road Traffic deaths in young drivers

Current Projects

- Suicide Prevention and Suicide Epidemiology
- Postcards from the Edge (RCT)
- Hunter Dialectical Behaviour Therapy Project (RCT)
- Case-control studies of completed and attempted suicide in young persons in NSW. (NHMRC)
- Coronial suicide note project (inc. U of Sydney)
- Explanations for the decline in young male suicide in Australia (inc. U of Queensland and UNSW)

Psycho-oncology

Case Finding Study (2 waves)

Carers Study

- Cognitive impairment in cancer patients (inc. Neuropsychiatry HNEMHS)
- Cross validation of SPHERE and HADS
- Cross validation of Distress Thermometer
- Depression and nutrition in head and neck cancer (inc. Dept Dietetics NMH)
- Psycho-social issues in prostate cancer (inc. Dept Radiation Oncology NMH)
- Screening for distress and psychopathology: Touchscreen project

Delirium and Toxicology of psycho-active medications

- Which drugs cause delirium in hospital-treated self-poisoning? (inc Dept Clinical Toxicology NMH)
- Genetic vulnerability to serotonin toxicity (inc NIH USA & Dept Clinical Toxicology NMH)

Road Traffic deaths in young drivers

- DRIVE study (inc. George Institute Sydney)

Consultation Liaison nursing

- You are not alone: results of the 2005 Australian CL Nurses survey (inc CL nursing colleagues from ACMHN CL SIG)

Recent publications

Carter G, Clover K, Whyte I, Dawson A, D'Este C. Postcards from the EDge: a randomised controlled trial to reduce the repetition of hospital-treated deliberate self-poisoning. *British Medical Journal* 2005; 331:805-807. (online version available September 2005)

Department of Consultation-Liaison Psychiatry

Parkinson L, Rainbird K, Kerridge I, Carter G, Cavenagh J, McPhee J, Ravenscroft P. Cancer patients' attitudes towards euthanasia and physician-assisted suicide: The influence of question wording and patients' own definitions on responses. *Journal of Bioethical Inquiry* September 2005; 2(2): 82-89.

Carter G, Safranko I, Lewin T, Whyte I, Bryant J. Psychiatric hospitalization after deliberate self-poisoning. *Suicide and Life-Threatening Behavior* April 2006; 36(2):213-222.

Carter GL, Clover KA, Parkinson L, Rainbird K, Kerridge I, Ravenscroft P, Cavenagh J, McPhee J. Mental health and other clinical correlates of euthanasia attitudes in an Australian outpatient cancer population. *Psycho-Oncology* Published online as Early View, 18th August 2006. DOI: 10.1002/pon.1058.

Page A, Morrell S, Taylor R, Carter G, Dudley M. Divergent trends in suicide by socio-economic status in Australia. *Social Psychiatry and Psychiatric Epidemiology* (published online version, 1 September 2006) 2006; 41:911-917

Haematology Clinical Trials Research Team

<heading> Data Managers:

Contact: Michele Gambrell

Office Manager

Clinical Trials Coordinator/Research Nurse

<bold> Phone: 02 4921 1217

<bold> Fax: 02 4921 1163

<bold> Email: michelle.gambrell@mater.health.nsw.gov.au

Contact: Tara Novak

Clinical Trials Coordinator/Research Nurse

<bold> Phone: 02 4921 1217

<bold> Fax: 02 4921 1163

<bold> Email: tara.novak@mater.health.nsw.gov.au

<heading> Administration:

Contact: Patricia Rozanski

Clinical Trials Administration Officer

<bold> Phone: 02 4921 1768

<bold> Fax: 02 4921 1163

<bold> Email: patricia.rozanski@mater.health.nsw.gov.au

<heading> Research Analyst:

Contact: Hong Zhang

<bold> Phone: 02 4921 1161

<bold> Fax: 02 4921 1163

<bold> Email: hong.zhang@mater.health.nsw.gov.au

Current number of patients enrolled in trials: 125

Number of current trials: 12

Number of trials closed to accrual but in Follow-up: 7

TITLES OF CURRENT TRIALS (Principal Investigator {PI} – Data Manager {DM})

<heading> ACUTE MYELOID LEUKAEMIA

<bold> ALLG AML M12 PI: Arno Enno DM: Tara Novak

A placebo-controlled, randomised Trial of the effects of palifermin on severe oral mucositis following intensive induction chemotherapy incorporating high dose cytosine and a randomised trial of Idarubicin dose Escalation in consolidation therapy in patients with Untreated Adult Acute Myeloid Leukaemia.

Department of Consultation-Liaison Psychiatry

<bold> ALLG AML M13 PI: Sandra Deveridge DM: Michele Gambrill

High dose cytarabine and Fludrabine without anthracycline for patients with core Binding Factor Acute Myeloid Leukaemia.

<bold>ALLG APML 4 PI: Michael Seldon DM: Michele Gambrill

A Phase II trial in patients with previously untreated Acute Promyelocytic Leukaemia (APML) to evaluate the effects of: i) adding arsenic trioxide to ATRA and idarubicin for remission induction and ii) adding arsenic trioxide to ATRA as consolidation

<heading> NON HODGKIN'S LYMPHOMA

<bold> NHL 14 - PI: Mark Walsh DM: Tara Novak

Watch and Wait – An inter group randomised trial of rituximab versus a watch and wait strategy in patients with advanced stage, asymptomatic, non-bulky follicular lymphoma.

<bold> ALLG NHL11 PI: Sandra Deveridge DM: Tara Novak

Hyper/CVAD – A phase II study of modified "Hyper-CVAD" frontline therapy for patients with poor prognosis diffuse large B-Cell and peripheral T-cell non-Hodgkin's lymphoma.

<bold> ALLG LY03 PI: Arno Enno DM: Tara Novak

WM + SLVL International randomised Study of Chlorambucil (max 12 cycles) vs fludarabine (max 6 cycles)

<heading> CHRONIC MYELOID LEUKAEMIA

<bold> ALLG CML ALL1 PI: Arno Enno DM: Tara Novak

A Phase II Pilot /study of Glivec combined with Induction Chemotherapy in blast-Phase CML and Ph + ve Acute Lymphoblastic Leukaemia (Denovo and relapsed).

<bold> STI571 GLIVEC PI: Philip Rowlings DM: Michele Gambrill

A randomized open-label of 400 mg v 800 mg of Glivec in patients with newly diagnosed, previously untreated chronic myeloid leukaemia in chronic phase. (CML-CP).

<heading> OTHER STUDIES

<bold> BIOSTATE

PI: Michael Seldon DM: Michele Gambrill Haemophilia Nurse: Kay Sheridan

A safety and effectiveness study of Biostate in patients with von Willebrand disease (CSLCT-CIO-03-97)

<bold> ASPIRE PI: Michael Seldon DM: Michele Gambrill

Placebo versus low-dose ASPIrin in the Prevention of Recurrent Venous Thromboembolism (ASPIRE)

<bold> BNP Study PI: Michael Seldon DM: Tara Novak

BNP testing in patient's receiving initial anthracycline. Using plasma from collected biochem samples.

<bolc> R-IE Study

Outpatient Ifosfamide, Etoposide plus Rituximab (R-IE) for salvage in patients > 60 years with relapsed or refractory CD20 positive diffuse large B-cell lymphoma who are not candidates for stem cell transplant.

<heading> AWAITING APPROVAL FROM ETHICS

<bold> BOMeR

Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse. An Australian Myeloma Forum Multi-Centre Phase II Trial This study was submitted to Ethics on 17th November, 2006.

<bold> RELAPSED CLL- BIOGEN STUDY

Randomised, open label, multicentre phase 2 study to evaluate the safety and efficacy of Lumiliximab in combination with Fludarabine, Cyclo, and Rituximab versus Fludarabine, Cyclo, and Rituximab alone in subjects with relapsed CLL.

Department of Consultation-Liaison Psychiatry

<bold> PROPOSED STUDIES

MM18 (Celgene) Multicenter, single- arm, open label safety study of Lenalidomide plus dexamethasone in previously treated pt's with MM

Oral tabs for 21 days every 28 days with oral pulse dexa (40mg days 1-4, 9-12 & 17-20 for each 28 day cycle for cycles 1-4. In cycle 5 Dex reduced to 40mg daily for days 1-4 every 28days. Treatment continues until disease progression.

<heading> CLOSED TO ACCRUAL

<bold> NON HODGKIN'S LYMPHOMA

LOW4 PI: Arno Enno DM: Michele Gambrell

MabThera for remission induction and maintenance of relapsed follicular NHL.

<bold> CHRONIC LYMPHOCYTIC LYMPHOMA

ALLG-CLL2 PI: Sandra Deveridge DM: Michele Gambrell

Australian Leukaemia Study Group (ALSF) International Study on Treatment of CLL.

CLL8 PI: Sandra Deveridge DM: Tara Novak

Randomised trial of chemotherapy agents Fludarabine and Cyclophosphamide +/-MabThera for patients with untreated CLL.

<bold> CHRONIC MYELOID LEUKAEMIA

ALLG CML6 – PI: Philip Rowlings DM: Michele Gambrell

A Phase II Study in adult patients with newly-diagnosed chronic myeloid leukaemia of, initial intensified glivec therapy and sequential combination therapy for non-responders.

<bold> MULTIPLE MYELOMA

ALLG MM6 – PI: Arno Enno DM: Tara Novak

This is a Phase III multi-centre open label randomised study of 224 patients of maintenance therapy, Prednisone and zometa +/- thalidomide for patients with MM following ASCT.

<bold>

ACUTE PROMYELOCYTIC LEUKAEMIA

APML3 – PI: Arno Enno DM: Michele Gambrell

A phase II trial of ATRA and intensive Idarubicin followed by molecular monitoring in patients with acute promyelocytic leukaemia.

<bold> NON HODGKIN'S LYMPHOMA

MDS

Azacitidine + BSC vs BSC +/-Chemo - PI: Arno Enno DM: Tara Novak

Randomised Trial of Azacitidine plus Best Supportive Care Versus Best Supportive Care +/- Chemotherapy for Myelodysplastic Syndromes (MDS)

Recent Publications:

<bullet point> Seebach JD, Stussi G, Passweg JR, Loberiza FR Jr, Gajewski JL, Keating A, Goerner M, Rowlings PA, Tiberghien P, Elfenbein GJ, Gale RP van Rood JJ, Reddy V, Gluckman E, Bolwell BJ, Klumpp TR, Horowitz MM, Ringden O, Barrett AJ; GVHD Working Committee of Center for International Blood and Marrow Transplant Research. ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biol Blood Marrow Transplant. 2005 Dec;11(12):1006-13.

<bullet point> Johnson W, Kerridge I, Milton C, Carr D, Enno A, Bray L, Booth A. Hospital in the home (HITH) care following autologous stem cell transplantation for lymphoma and multiple myeloma. Aust J Adv Nurs. 2006 Jun-Aug;23(4):34-9.

<bullet point> Enjeti AK, Walsh M, Seldon M. Spontaneous major bleeding in acquired factor X deficiency secondary to AL-amyloidosis. Haemophilia. 2005;11(5):535-8.

7.3 Immunology and Oncology

Department of Consultation-Liaison Psychiatry

<bold> Contact: C/Professor Peter Hersey

<bold> Phone: 02 49236828

<bold> Fax: 02 49236184

<bold> Email: Peter.Hersey@newcastle.edu.au

<bold> Staff:

C/Professor Peter Hersey

Dr. Xu Dong Zhang

Mrs. Margaret Farrelly

Dr. Kelly Kiejda

Dr. Ralph Watts

Dr. Bike Zhu

Mr. Nizar Mhaidat

Ms. Chen Chen Jiang

Dr. Lihua Chen

Ms. Elise MacPherson

Mrs. Christine Cook

<heading> Research Interests

1. Cell death pathways in melanoma and resistance of melanoma to chemotherapy.
2. Immune responses against melanoma and immunotherapy.

<heading> Current Projects

1. NH&MRC – Resistance of melanoma cells to chemotherapy.
2. NH&MRC – Molecular determinants of risk, progression and treatment response in melanoma.
3. NSW SCC – The role of TRAIL in induction of apoptosis of melanoma.

<heading> Recent publications

Hersey, P., Menzies, S.W., Coventry, B., Nguyen, T., Farrelly, M., Collins, S., Hirst, D., and Johnson, H. (2005) Phase I/II study of immunotherapy with T cell peptide epitopes in patients with stage IV melanoma. *Cancer Immunology Immunotherapy* 54(3): 208-218. (IF: 3.130)

Gillespie, S.K., Zhang, X.D. and Hersey, P. (2004) Ingenol 3-angelate induces dual modes of cell death and differentially regulates TRAIL-induced apoptosis in melanoma cells. *Molecular Cancer Therapeutics* 3:1651-1658. (IF: 3.201) Bron, L.P., Scolyer, R.A.,

Thompson, J.F. and Hersey, P. (2004) Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma. *Pathology* 36(6):561-565. (IF: 1.112)

Gillespie, S., Zhang, X.D. and Hersey, P. (2005) Variable expression of protein kinase C epsilon in human melanoma cells regulates sensitivity to TRAIL-induced apoptosis. *Molecular Cancer Therapeutics* 4(4):668-76. (IF: 3.201)

Byrne, C.M., Thompson, J.F., Johnston, H., Hersey, P., Quinn, M.J., Hughes, T.M. and McCarthy, W.H. (2005) Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). *Melanoma Research* 15:45-51.

Allen, J.D., Zhang, X.D., Scott, C.L., Boyle, G.M., Hersey, P. and Strasser, A. (2005) Is Apaf-1 expression frequently abrogated in melanoma? (Letter) *Cell Death & Differentiation* 12(6):680-1.

Wu, J.J., Zhang, X.D., Gillespie, S. and Hersey, P. (2005) Selection for TRAIL resistance results in melanoma cells with high proliferative potential. *FEBS Letters* 579(9):1940-1944.

Zhuang, L., Lee, C.S., Scolyer, R.A., McCarthy, S.W., Palmer, A.A., Zhang X.D., Thompson, J.F., Bron, L.P. and Hersey, P. (2005) Activation of the extracellular-signal related kinase (ERK) pathway in human melanoma. *J. Clin. Pathology* 58(11):1163-1169. IF: 2.966

Millward, M.J., Joshua, A., Kefford, R., Aamdal, S., Thomson, D., Hersey, P., Toner, G. and Lynch, K. (2005) Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma. *Invest. New Drugs* 23(3):253-6.

Zhang, X.D., Wu, J.J., Gillespie, S.K., Borrow, J.M., and Hersey, P. (2006) Human melanoma cells selected for resistance to apoptosis by prolonged exposure to TRAIL are more vulnerable to necrotic cell death induced by Cisplatin. *Clin. Cancer Res.* 12(4):1355-1364. IF: 6.511

Department of Consultation-Liaison Psychiatry

- Hersey, P. Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma. (2006) *Current Opinion in Oncology* 18:189-196. IF: 4.544
- Hersey, P., Zhuang, L., and Zhang, X.D. Current strategies in overcoming resistance of cancer cells to apoptosis melanoma as a model. (2006) *International Review of Cytology* 251:131-158.
- Zhuang, L., Lee, C.S., Scolyer, R.A., McCarthy, S.W., Zhang, X.D., Thompson, J.F., Screaton, G., and Hersey, P. (2006) Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). *Human Pathology* 37:1286-1294.
- Bedikian, A., Millward, M., Pehamberger, H., Conry, R., Gore, M., Sterry, W., Pavlick, A.C., DeConti, R., Hersh, E.M., Hersey, P., Kirkwood, J.M., Haluska, F.G., the Oblimersen Melanoma Study Group. (2006) Bcl-2 antisense (Oblimersen Sodium) plus Dacarbazine in patients with advanced melanoma. *J. Clin. Oncol.* 24:4738-4745.
- Yu, F., Watts, R., Zhang, X.D., Borrow, J.M., and Hersey, P. (2006) Involvement of BH3 only proapoptotic proteins in mitochondrial dependent Phenoxodiol induced apoptosis of human melanoma cells. *Anticancer Drugs* 17(10):1151-1161.
- Gillespie, S., Borrow, J., Zhang, X.D., and Hersey, P. (2006) Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells. *Apoptosis* 11(12):2251-2265.
- Zhang, X.D., Wu, J.J., Gillespie, S., Borrow, J., and Hersey, P. (2006) Cross resistance of melanoma to trail-induced apoptosis and chemotherapy. *Update on Cancer Therapeutics* (in press).
- Mhaidat, N.M., Wang, Y., Kiejda, K., Zhang, X.D., and Hersey, P. (2006) Docetaxel induced apoptosis in melanoma is dependent on activation of Caspase 2. *Mol. Canc. Therapeutics* (in press).
- Mhaidat, N.M., Zhang, X.D., Jiang, C.C., and Hersey, P. (2006) Docetaxel-induced apoptosis of human melanoma is mediated by activation of JNK and inhibited by the MAPKinase ERK1/2 pathway. *Clinical Cancer Research* (Accepted for publication).
- Zhuang, L., Lee, C.S., Scolyer, R.A., McCarthy, S.W., Zhang, X.D., Thompson, J.F., and Hersey, P. (2006) Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. *Modern Pathology* (in press).

<heading> Book Chapters

- Zhang, X.D., Wu, J.J., Gillespie, S., Borrow, J. and Hersey, P. (2005) Cross resistance of melanoma to TRAIL induced apoptosis and chemotherapy. In: *Cancer Chemotherapy & Biological Response Modifiers Annual*.
- Hersey, P. (2005) Immunotherapy of Melanoma – Past, Present and Future. In: *Cancer Forum*. The Cancer Council, Australia.
- Hersey, P., Zhuang, L. and Zhang, X.D. (2006). Current strategies in overcoming resistance of cancer cells to apoptosis. Melanoma as a model. In: *International Review of Cytology – A Survey of Cell Biology*. Ed: Jeon, K.W. Elsevier, California. P131-158.
- Hersey, P. (2006). Apoptosis and Melanoma. How new insights are effecting the development of new therapies for melanoma. In: *Current Opinion in Oncology* (in press).
- Hersey, P., Zhang, X.D. and Mhaidat, N. (2006). Overcoming resistance to apoptosis in cancer therapy. In: *Programmed Cell Death in Cancer Progression and Therapy*. Eds: Khosravi-Far, R. and White, E. (in press).

7.4 Newcastle Melanoma Unit

<bold> Contact: C/Professor Peter Hersey
<bold> Phone: 02 49236828
02 49850100
<bold> Email: Peter.Hersey@newcastle.edu.au

<bold> Contact: RN Sue Collins
<bold> Phone: 02 49850110
<bold> Email: Susan.Collins@mater.health.nsw.gov.au

<bold> Contact: Dr. Pauline Hanrahan
<bold> Phone: 02 49850179

Department of Consultation-Liaison Psychiatry

<bold> Email: Pauline.Hanrahan@mater.health.nsw.gov.au

<bold> Fax: 02 49850101

<heading> Current Clinical Trials

Co-Investigator – Randomized Trial of Sentinel Node Biopsy in Stage II, III Melanoma.

MSLT-11 Commenced 8/2005. Ongoing.

Principal Investigator – A Phase I Study of Intralesional PV-10 Chemoablation in Subjects with Metastatic Melanoma. Commenced 9/2005.

Co-Investigator - Phase 2 Clinical Trial of 17-allylamino-17-demethoxy-geldanamycin (KOS-953) in Metastatic Melanoma. Sponsor: Kosan Biosciences. Commenced May 2006.

Co-Investigator – Phase 2, Open Label, Single Arm Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of CP-675,206 in Patients with Advanced Refractory and/or Relapsed Melanoma (A3671008). Sponsor: Pfizer. Commenced May 2006.

Co-Investigator – A Phase 3, Open Label, Randomized, Comparative Study of Tiviclumab and Either Dacarbazine or Temozolomide in Patients with Advanced Melanoma (A3671009). Sponsor: Pfizer. Commenced May 2006.

Co-Investigator – A Phase II, Multi-centre, Open-Label, Parallel Group, Randomised Study to Assess the Safety and Efficacy of AZD6244 vs Temozolomide in Subjects with Unresectable AJCC Stage 3 or 4 Malignant Melanoma. Sponsor: AstraZeneca. Commenced June 2006.

Co-Investigator – A Phase III Randomized, Double Blind, Multinational, Multicenter Study of Study Therapy in Combination with Dacarbazine in Treating Patients with Unresectable, Stage IV or Recurrent Stage III Melanoma (CA184-024). Sponsor: Medarex/Bristol Myer Squibb. (To be commenced)

Co-Investigator – A Randomized, Double-Blind, Multi-center, Phase II Fixed Dose Study of Multiple Doses of BMS-734016 (MDXI-010) Monotherapy in Patients with Previously Treated Unresectable Stage III or IV Melanoma (CA184-022). Sponsor: Medarex/Bristol Myer Squibb. (To be commenced)

<heading> Recent publications

Hersey, P., Menzies, S.W., Coventry, B., Nguyen, T., Farrelly, M., Collins, S., Hirst, D., and Johnson, H. (2005) Phase I/II study of immunotherapy with T cell peptide epitopes in patients with stage IV melanoma. *Cancer Immunology Immunotherapy* 54(3): 208-218. (IF: 3.130)

Gillespie, S.K., Zhang, X.D. and Hersey, P. (2004) Ingenol 3-angelate induces dual modes of cell death and differentially regulates TRAIL-induced apoptosis in melanoma cells. *Molecular Cancer Therapeutics* 3:1651-1658. (IF: 3.201) Bron, L.P., Scolyer, R.A.,

Thompson, J.F. and Hersey, P. (2004) Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma. *Pathology* 36(6):561-565. (IF: 1.112)

Gillespie, S., Zhang, X.D. and Hersey, P. (2005) Variable expression of protein kinase C epsilon in human melanoma cells regulates sensitivity to TRAIL-induced apoptosis. *Molecular Cancer Therapeutics* 4(4):668-76. (IF: 3.201)

Byrne, C.M., Thompson, J.F., Johnston, H., Hersey, P., Quinn, M.J., Hughes, T.M. and McCarthy, W.H. (2005) Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). *Melanoma Research* 15:45-51.

Allen, J.D., Zhang, X.D., Scott, C.L., Boyle, G.M., Hersey, P. and Strasser, A. (2005) Is Apaf-1 expression frequently abrogated in melanoma? (Letter) *Cell Death & Differentiation* 12(6):680-1.

Wu, J.J., Zhang, X.D., Gillespie, S. and Hersey, P. (2005) Selection for TRAIL resistance results in melanoma cells with high proliferative potential. *FEBS Letters* 579(9):1940-1944.

Zhuang, L., Lee, C.S., Scolyer, R.A., McCarthy, S.W., Palmer, A.A., Zhang X.D., Thompson, J.F., Bron, L.P. and Hersey, P. (2005) Activation of the extracellular-signal related kinase (ERK) pathway in human melanoma. *J. Clin. Pathology* 58(11):1163-1169. IF: 2.966

Millward, M.J., Joshua, A., Kefford, R., Aamdal, S., Thomson, D., Hersey, P., Toner, G. and Lynch, K. (2005) Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma. *Invest. New Drugs* 23(3):253-6.

Zhang, X.D., Wu, J.J., Gillespie, S.K., Borrow, J.M., and Hersey, P. (2006) Human melanoma cells selected for resistance to apoptosis by prolonged exposure to TRAIL are more vulnerable to necrotic cell death induced by Cisplatin. *Clin. Cancer Res.* 12(4):1355-1364. IF: 6.511

Hersey, P. Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma. (2006) *Current Opinion in Oncology* 18:189-196. IF: 4.544

Department of Consultation-Liaison Psychiatry

- Hersey, P., Zhuang, L., and Zhang, X.D. Current strategies in overcoming resistance of cancer cells to apoptosis melanoma as a model. (2006) *International Review of Cytology* 251:131-158.
- Zhuang, L., Lee, C.S., Scolyer, R.A., McCarthy, S.W., Zhang, X.D., Thompson, J.F., Screaton, G., and Hersey, P. (2006) Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). *Human Pathology* 37:1286-1294.
- Bedikian, A., Millward, M., Pehamberger, H., Conry, R., Gore, M., Sterry, W., Pavlick, A.C., DeConti, R., Hersh, E.M., Hersey, P., Kirkwood, J.M., Haluska, F.G., the Oblimersen Melanoma Study Group. (2006) Bcl-2 antisense (Oblimersen Sodium) plus Dacarbazine in patients with advanced melanoma. *J. Clin. Oncol.* 24:4738-4745.
- Yu, F., Watts, R., Zhang, X.D., Borrow, J.M., and Hersey, P. (2006) Involvement of BH3 only proapoptotic proteins in mitochondrial dependent Phenoxodiol induced apoptosis of human melanoma cells. *Anticancer Drugs* 17(10):1151-1161.
- Gillespie, S., Borrow, J., Zhang, X.D., and Hersey, P. (2006) Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells. *Apoptosis* 11(12):2251-2265.
- Zhang, X.D., Wu, J.J., Gillespie, S., Borrow, J., and Hersey, P. (2006) Cross resistance of melanoma to trail-induced apoptosis and chemotherapy. *Update on Cancer Therapeutics* (in press).
- Mhaidat, N.M., Wang, Y., Kiejda, K., Zhang, X.D., and Hersey, P. (2006) Docetaxel induced apoptosis in melanoma is dependent on activation of Caspase 2. *Mol. Canc. Therapeutics* (in press).
- Mhaidat, N.M., Zhang, X.D., Jiang, C.C., and Hersey, P. (2006) Docetaxel-induced apoptosis of human melanoma is mediated by activation of JNK and inhibited by the MAPKinase ERK1/2 pathway. *Clinical Cancer Research* (Accepted for publication).
- Zhuang, L., Lee, C.S., Scolyer, R.A., McCarthy, S.W., Zhang, X.D., Thompson, J.F., and Hersey, P. (2006) Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. *Modern Pathology* (in press).

<heading> **Book Chapters**

- Zhang, X.D., Wu, J.J., Gillespie, S., Borrow, J. and Hersey, P. (2005) Cross resistance of melanoma to TRAIL induced apoptosis and chemotherapy. In: *Cancer Chemotherapy & Biological Response Modifiers Annual*.
- Hersey, P. (2005) Immunotherapy of Melanoma – Past, Present and Future. In: *Cancer Forum*. The Cancer Council, Australia.
- Hersey, P., Zhuang, L. and Zhang, X.D. (2006). Current strategies in overcoming resistance of cancer cells to apoptosis. Melanoma as a model. In: *International Review of Cytology – A Survey of Cell Biology*. Ed: Jeon, K.W. Elsevier, California. P131-158.
- Hersey, P. (2006). Apoptosis and Melanoma. How new insights are effecting the development of new therapies for melanoma. In: *Current Opinion in Oncology* (in press).
- Hersey, P., Zhang, X.D. and Mhaidat, N. (2006). Overcoming resistance to apoptosis in cancer therapy. In: *Programmed Cell Death in Cancer Progression and Therapy*. Eds: Khosravi-Far, R. and White, E. (in press).

7.5 Palliative Care Research

<bold> Contact: Dr Phillip Good
<bold> Phone: 4921 1957
<bold> Fax: 4921 1952
<bold> Email: Phillip.Good@mater.health.nsw.gov.au

<heading> Staff:

<heading> Research Interests
See projects

<heading> Current Projects
<bullet point> Oral care
<bullet point> Ethics of end of life care

Department of Consultation-Liaison Psychiatry

- <bullet point> Perceptions of the Palliative Care service from the viewpoint of Community nurses and General Practitioners in the Hunter Area
- <bullet point> Nurses' and Doctors' perceptions and attitudes of patients' nutrition and hydration at the end of life
- <bullet point> Death education

<heading> Recent publications

- Schneider JJ, Good P, Ravenscroft PJ. Effect of Tubing on Loss of Clonazepam Administered by Continuous Subcutaneous Infusion. *J Pain Symptom Manage* 2006;31:563-7
- Cavenagh J, Good P, Ravenscroft P. Neuropathic pain: are we out of the woods yet? *Internal Medicine Journal* 2006;36:251-5
- Good PD, Cavenagh JD, Currow DC, Woods DA, Tuffin PH, Ravenscroft PJ. What are the essential medications in palliative care? - a survey of Australian palliative care doctors. *Aust Fam Physician* 2006;35:261-4.
- Good P. Re: efficacy, safety, and ethical validity of palliative sedation therapy. *J Pain Symptom Manage* 2006;31:196-7.
- Good PD, Ravenscroft PJ, Cavenagh J. Effects of opioids and sedatives on survival in an Australian inpatient palliative care population. *Intern Med J* 2005;35:512-517
- Parkinson L, Rainbird K, Kerridge I, Carter G, Cavenagh J, McPhee J, Ravenscroft P. Cancer Patients' Attitudes Towards Euthanasia and Physician-Assisted Suicide: The influence of question wording and patients' own definitions on responses. *J. Bioethical Inquiry* 2005;2:82-89.
- Terry W, Olson LG, Ravenscroft P, Wilss L, Boulton-Lewis G. Hospice patients' views on research in palliative care. *Internal Medicine Journal* 2006;36:406-413.
- Cavenagh J, Good P, Ravenscroft P. Neuropathic Pain: Are we out of the woods yet? *Internal Med J.* 2006;36:251-255
- Good P. Re: efficacy, safety, and ethical validity of palliative sedation therapy. *J Pain Symptom Manage* 2006;31:196-7.
- van der Riet. P; Higgins, I; Good, P and M, Sneesby (2006). Nurses' and Doctors' perceptions and attitudes of patients' nutrition and hydration at the end of life. Paper presented at Australian Association of Gerontology Conference. Positive Ageing. Something to Sing about. March. Tamworth.
- Good PD, Ravenscroft PJ, Cavenagh J. Effects of opioids and sedatives on survival in an Australian inpatient palliative care population. *Intern Med J* 2005;35:512-517.
- Good P, Tullio F, Jackson K, Goodchild C, Ashby M. Prospective audit of short-term concurrent ketamine, opioid and anti-inflammatory ('triple-agent') therapy for episodes of acute on chronic pain. *Intern Med J.* 2005 Jan;35(1):39-44.

<heading> Book Chapters

- Ravenscroft PJ. (Chairman of the Writing Group)
Therapeutic Guidelines: Palliative Care. Version 2. Therapeutic Guidelines Limited. North Melbourne. 2005.

7.6 The Hunter Haematology Research Group

- <bold> Contact: Dr. Lisa Lincz, Snr. Hospital Scientist
- <bold> Phone: +61 2 49211844
- <bold> Fax: +61 2 49602136
- <bold> Email: lisa.lincz@newcastle.edu.au

<heading> Staff:

- Fiona Scorgie , Hospital Scientist
- Sharon Nash, Technical Officer
- Linda Bisset, Technical Officer

<heading> Research Interests

Department of Consultation-Liaison Psychiatry

The Hunter Haematology Research Group performs laboratory based research into the causes and treatment of haematological malignancies and thrombotic disorders. The group works closely with clinicians and data managers in order to conduct most of their studies on actual patient samples. The group is actively involved in trials run through the Australian Leukaemia and Lymphoma group, forming part of the network of laboratory support that is vital to the success of clinical trials.

<heading> Current Projects

- <bullet point> mechanisms of drug resistance in APLM
- <bullet point> overcoming radiation resistance in melanoma
- <bullet point> epigenetics of atherothrombotic disease
- <bullet point> mechanisms of snakebite coagulopathy
- <bullet point> microparticles as predictors of bleeding and/or thrombosis
- <bullet point> investigating a novel target on the surface of leukaemia cells

<heading> Recent publications

- Lincz L F, Crooks R L, Way S, Granter N, Spencer A (2001) Tumour kinetics in multiple myeloma before, during, and after treatment. *Leukaemia & Lymphoma* 40:373-384.
- Lincz LF, Yeh T-X and Spencer, A. (2001) Variations in trail-induced apoptosis of primary multiple myeloma tumour cells are not related to trail-receptor expression or prior chemotherapy. *Leukemia* 15;1650-1657
- Kerridge I, Lincz LF, Scorgie FE, Granter N, Hickey D, Enno A, Spencer A (2002). Xenobiotic enzyme polymorphisms and lymphoma susceptibility *Br. J. Haematol* 118;477-481.
- Sakoff, JA, De Waal E, Garg M, Denham J, Scorgie FE, Enno A, Lincz LF, Ackland SP (2002) Telomere length in haematopoietic stem cells can be determined from that of mononuclear blood cells or whole blood. *Leukemia & Lymphoma* 43(10)2017-2020
- Lincz, LF, Scorgie FE, Kerridge I, Potts R, Spencer A, Enno A (2003). Methionine synthase genetic polymorphism MS A2756G alters susceptibility to Follicular but not Diffuse Large B-Cell Non-Hodgkin's Lymphoma or Multiple Myeloma. *Br. J. Haematol* 120;1051-1054
- Lincz LF, Kerridge I, Scorgie FE, Bailey M, Enno A, Spencer A (2004) Xenobiotic gene polymorphisms and increased risk of multiple myeloma *Haematologica* 89 (5): 628-629
- Lincz LF, Scorgie FE, Sakoff JA, Fagan KA, Ackland SP, Enno A (2004) Telomere length predicts neutrophil recovery in the absence of GCSF after autologous peripheral blood stem cell transplantation. *Bone Marrow Transplantation* 34(5):439-45
- Lincz LF, Fiona E Scorgie, Richard Robertson, Arno Enno (2006) Genetic variations in benzene metabolism and susceptibility to Multiple Myeloma. *Leukemia Research* (In press)

8.0 Contact Us

<heading> Information Desk

You can find the Information Desk located on Level 3, main entrance, Edith Street, Waratah. Our staff will assist you with your admission, patient location and directions to departments. Transport timetables are on display in the foyer. Our cashier is also located next to the Information Desk in the main foyer should you require change for car parking.

<heading> Street Address

<bold> Corner Edith & Platt Streets, Waratah, NSW 2298

<heading> Postal Address:

Calvary Mater Newcastle, Locked Bag 7, Hunter Region Mail Centre NSW 2310

Please [click here](#) for a Location Map. <live link>

<heading> Main Contact Numbers

Telephone number: (02) 4921 1211 <bold> (in case of emergency ALWAYS dial 000)

<bold> Enquiries (02) 4921 1211

Department of Consultation-Liaison Psychiatry

Accommodation bookings: (02) 4921 1405

<heading> Complaints / Compliments

Calvary Mater Newcastle is committed to meeting the needs and expectations of our patients in providing a service of excellence. We will strive to ensure that your stay with us is comfortable and that your needs are met by all of our staff. If you have any concerns, or would like to make a comment on your care at Calvary Mater Newcastle, we encourage you to speak, in the first instance, with the staff in your ward/unit. Should you, however, wish to make a formal complaint, or if you would like to discuss your care with hospital management then you are welcome to address your telephone call or correspondence to the General Manager, or to either of the Directors of Clinical Services, Medical or Nursing. Telephone numbers are as follows:

** General Manager - (02) 4014 4700**

** Director of Clinical Services (Medical) - (02) 4014 4707**

** Director Clinical Services (Nursing) - (02) 4014 4710**

Postal Address: Calvary Mater Newcastle, Locked Bag 7, Hunter Region Mail Centre NSW 2310

Calvary Mater Newcastle also appreciates your input of your positive experiences, so please let us know!

You can also [contact us by email](#) <live link>.

<heading> Information for You

Every patient has rights and responsibilities - find out more by downloading the brochure.

[Your Health Rights and Responsibilities](#) (PDF ~ 6.4MB)<pdf link>

Alternatively, you may wish to discuss your concerns with your doctor.

Should you, however, wish to make a formal complaint, or if you would like to discuss your care with hospital management then you are welcome to address your telephone call or correspondence to the General Manager, or to either of the Directors of Clinical Services, Medical or Nursing. Telephone numbers are as follows:

** General Manager - (02) 4014 4700**

** Director of Clinical Services (Medical) - (02) 4014 4707**

** Director Clinical Services (Nursing) - (02) 4014 4710**

Postal Address: Calvary Mater Newcastle, Locked Bag 7, Hunter Region Mail Centre NSW 2310

<heading> Suggestions

Ideas and feedback may be submitted in writing to the General Manager, Calvary Mater Newcastle, Locked Bag 7, Hunter Region Mail Centre NSW 2310.

A suggestion box is also located across from the Information Desk on level 3 in the main foyer next to the ATM . We welcome and encourage feedback from our patients and visitors.

For complaints, please complete the following form:

[Complaints <live link to pdf>](#)